4598 is currently developing the following drugs: Venetoclax, Dfp-10917, Dfp-14927, Fludarabine, Azacitidine, Cytarabine, Decitabine, Venetoclax, Etoposide, Idarubicin, Mitoxantrone, Dfp-10917, Cladribine. These drug candidates are in various stages of clinical development as the company works toward FDA approval.